MicroRNA-150: A novel marker of left ventricular remodeling after acute myocardial infarction

Circulation: Cardiovascular Genetics

Volumn 6, Issue 3, 2013, Pages 290-298

  Devaux, Yvan ^a   Vausort, Melanie ^a   McCann, Gerry P ^b   Zangrando, Jennifer ^a   Kelly, Dominic ^b   Razvi, Naveed ^b   Zhang, Lu ^a   Ng, Leong L ^b   Wagner, Daniel R ^a,c   Squire, Iain B ^b  

^a LUXEMBOURG INSTITUTE OF HEALTH   (Luxembourg)

^b UNIVERSITY OF LEICESTER   (United Kingdom)

^c Centre Hospitalier   (Luxembourg)

Author keywords

Biomarker; MicroRNA; Myocardial infarction; Remodeling

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; CREATINE KINASE; MICRORNA; MICRORNA 150; TROPONIN I; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; GENE EXPRESSION; HEART INFARCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; ST SEGMENT ELEVATION; VALIDATION PROCESS;

BIOMARKER; MICRORNA; MYOCARDIAL INFARCTION; REMODELING;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; COHORT STUDIES; FEMALE; HUMANS; MALE; MICRORNAS; MIDDLE AGED; MYOCARDIAL INFARCTION; VENTRICULAR REMODELING;

EID: 84880514093     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000077     Document Type: Article

References (40)

1. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008;358: 2148-2159.
2. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-Type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
3. Haeck JD, Verouden NJ, Kuijt WJ, Koch KT, Van Straalen JP, Fischer J, et al. Comparison of usefulness of N-Terminal pro-brain natriuretic peptide as an independent predictor of cardiac function among admission cardiac serum biomarkers in patients with anterior wall versus nonanterior wall ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Am J Cardiol. 2010;105:1065-1069.
4. Sabatine MS, Morrow DA, de Lemos JA, Gibson CM, Murphy SA, Rifai N, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-Type natriuretic peptide. Circulation. 2002;105:1760-1763.
5. Talwar S, Squire IB, Downie PF, Mccullough AM, Campton MC, Davies JE, et al. Profile of plasma N-Terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J. 2000;21:1514-1521.
6. van Rooij E. Introduction to the series on microRNAs in the cardiovascular system. Circ Res. 2012;110:481-482.
7. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, et al. Serum microRNAs are promising novel biomarkers. PLoS One. 2008;3:e3148.
8. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 2008;105:10513-10518.
9. Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res. 2012;110:483-495.
10. Divakaran V, Mann DL. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res. 2008;103:1072-1083.
11. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation. 2007;116:258-267.
12. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, et al. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci USA. 2006;103:18255-18260.
13. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res. 2007;100:416-424.
14. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, et al. MiR423-5p as a circulating biomarker for heart failure. Circ Res. 2010;106:1035-1039.
15. Latronico MV, Condorelli G. microRNAs in hypertrophy and heart failure. Exp Biol Med (Maywood). 2011;236:125-131.
16. Widera C, Gupta SK, Lorenzen JM, Bang C, Bauersachs J, Bethmann K, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. J Mol Cell Cardiol. 2011;51:872-875.
17. Zile MR, Mehurg SM, Arroyo JE, Stroud RE, Desantis SM, Spinale FG. Relationship between the temporal profile of plasma microrna and left ventricular remodeling in patients following myocardial infarction. Circ Cardiovasc Genet. 2011;4:614-619.
18. Devaux Y, Vausort M, Goretti E, Nazarov PV, Azuaje F, Gilson G, et al. Use of circulating microRNAs to diagnose acute myocardial infarction. Clin Chem. 2012;58:559-567.
19. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, et al. Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J. 2007;28:711-718.
20. Steadman CD, Jerosch-Herold M, Grundy B, Rafelt S, Ng LL, Squire IB, et al. Determinants and functional significance of myocardial perfusion reserve in severe aortic stenosis. JACC Cardiovasc Imaging. 2012;5:182-189.
21. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-Terminal pro-B-Type natriuretic peptide and long-Term mortality in acute coronary syndromes. Circulation. 2002;106:2913-2918.
22. Karl J, Borgya A, Gallusser A, Huber E, Krueger K, Rollinger W, et al. Development of a novel, N-Terminal-proBNP (NT-proBNP) assay with a low detection limit. Scand J Clin Lab Invest Suppl. 1999;230:177-181.
23. Pencina MJ, D'Agostino RB Sr, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med. 2011;30:11-21.
24. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172.
25. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, et al. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol. 2007;42:1137-1141.
26. Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, et al. Decreased catecholamine sensitivity and beta-Adrenergic-receptor density in failing human hearts. N Engl J Med. 1982;307:205-211.
27. Ørn S, Manhenke C, Ueland T, Damas JK, Mollnes TE, Edvardsen T, et al. C-reactive protein, infarct size, microvascular obstruction, and leftventricular remodelling following acute myocardial infarction. Eur Heart J. 2009;30:1180-1186.
28. Donners MM, Beckers L, Lievens D, Munnix I, Heemskerk J, Janssen BJ, et al. The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood. 2008;111:4596-4604.
29. Azuaje FJ, Dewey FE, Brutsaert DL, Devaux Y, Ashley EA, Wagner DR. Systems-based approaches to cardiovascular biomarker discovery. Circ Cardiovasc Genet. 2012;5:360-367.
30. Dewey FE, Perez MV, Wheeler MT, Watt C, Spin J, Langfelder P, et al. Gene coexpression network topology of cardiac development, hypertrophy, and failure. Circ Cardiovasc Genet. 2011;4:26-35.
31. Pham MX, Teuteberg JJ, Kfoury AG, Starling RC, Deng MC, Cappola TP, et al IMAGE Study Group. Gene-expression profiling for rejection surveillance after cardiac transplantation. N Engl J Med. 2010;362:1890-1900.
32. Abdellatif M. Differential expression of microRNAs in different disease states. Circ Res. 2012;110:638-650.
33. Zidar N, Boštjančič E, Glavač D, Stajer D. MicroRNAs, innate immunity and ventricular rupture in human myocardial infarction. Dis Markers. 2011;31:259-265.
34. Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A, Ferracin M, et al. MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. PLoS One. 2009;4:e7405.
35. Wang Y, Li Z, He C, Wang D, Yuan X, Chen J, et al. MicroRNAs expression signatures are associated with lineage and survival in acute leukemias. Blood Cells Mol Dis. 2010;44:191-197.
36. Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell. 2010;39:133-144.
37. Tano N, Kim HW, Ashraf M. microRNA-150 regulates mobilization and migration of bone marrow-derived mononuclear cells by targeting Cxcr4. PLoS One. 2011;6:e23114.
38. Lin RCY, Weeks KL, Gao X-M, Williams RBH, Bernardo BC, Kiriazis H, et al. PI3K(p110α) protects against myocardial infarction-induced heart failure. Arterioscler Thromb Vasc Biol. 2010;30:724-732.
39. Tijsen AJ, Pinto YM, Creemers EE. Non-cardiomyocyte microRNAs in heart failure. Cardiovasc Res. 2012;93:573-582.
40. Kelly D, Khan SQ, Thompson M, Cockerill G, Ng LL, Samani N, et al. Plasma tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9: novel indicators of left ventricular remodelling and prognosis after acute myocardial infarction. Eur Heart J. 2008;29:2116-2124.